DeepScan Raises $3.5M to Make Real-Time Precision Health Monitoring the New Standard
HELSINKI — April 22, 2026
DeepScan Diagnostics, a pioneer in canine cell-free DNA (cfDNA) diagnostics, today announced $3.5 million in funding to scale its cfDNA health monitoring platform. The round was led by Vienna-based healthtech VC Calm/Storm, an existing investor that doubled down on its commitment to the company, with additional participation from Finnish family office Harjavalta and a consortium of European family offices,prominent angel investors and Business Finland
A New Kind of Health Signal
cfDNA, tiny fragments of DNA released into the bloodstream when cells break down, is one of the most powerful and versatile biomarkers in modern medicine. Elevated cfDNA levels are a direct signal of systemic cell damage, making them a sensitive early indicator across a broad range of conditions: from cancer and severe chronic disease to acute injury and organ damage.
DeepScan's flagship product, the CFD® marker, measures these cfDNA levels from a simple blood draw. Since its market debut last year, the test has been adopted by approximately 100 veterinary clinics and animal hospitals across the United States, the United Kingdom, and Finland.
Unlike traditional diagnostics, the CFD® marker gives veterinarians a fast, non-invasive method to detect hidden disease, assess condition severity, and, most critically, track how a patient is responding to treatment in near real-time.
From Months of Uncertainty to Days of Clarity
The limitations of current veterinary diagnostics are most stark in cancer care, where standard chemotherapy and radiation protocols can last between 20 and 40 weeks. Under existing standards, clinicians and pet owners often must wait until the very end of these grueling protocols to learn whether treatment is working.
By tracking cfDNA levels, veterinarians can gauge treatment response in as little as one to two weeks, enabling immediate adjustments to care plans rather than months of uncertainty. The same principle extends to monitoring recovery from acute illness, managing chronic disease progression, and flagging early deterioration before clinical symptoms appear.
"Our profession has been searching for an ease of use, affordable and accurate blood test that can serve as an aid in cancer diagnosis and a tool for treatment monitoring" said Dr. Zachary Wright, member and former chair of the Mars Veterinary Health Oncology Advisory Board. "CFD has the potential to fundamentally improve how cancer treatments are planned in the future, providing better outcomes for our patients and clarity for their families."
Clinical Validation and Technical Foundation
The precision of the CFD® marker is underpinned by one of the industry's most extensive proprietary datasets: over 6,000 breed-specific samples from 4,000 individual dogs, growing daily. This dataset enables highly calibrated insights that account for natural biological variance between breeds, a critical factor in distinguishing meaningful health signals from background noise.
Use of Funds
The newly raised capital will be deployed across three areas:
- Scale Clinical Studies: Advancing ongoing research to further validate CFD®’s efficacy across oncology, chronic disease management, and acute care settings.
- Expand Use Cases: Extending CFD® biomarker applications into emergency care and long-term chronic disease monitoring.
- Global Onboarding: Beginning in late 2026, onboarding the hundreds of veterinary clinics currently on the company's international waitlist.
"The reception from veterinarians worldwide has been extremely positive because we are addressing the most agonizing part of any serious diagnosis: the uncertainty," said William von der Pahlen, CEO & Co-Founder of DeepScan Diagnostics. "With this funding, we are moving from a successful market entry to becoming the global standard for precision health monitoring in veterinary medicine."